INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,811,156 | +711.6% | 149,955 | +886.5% | 0.02% | +566.7% |
Q2 2023 | $962,464 | -92.2% | 15,200 | -93.3% | 0.00% | -98.4% |
Q1 2023 | $12,346,308 | +0.9% | 228,002 | -1.4% | 0.18% | -17.0% |
Q4 2022 | $12,241,031 | +10.6% | 231,312 | -2.8% | 0.22% | +5.2% |
Q3 2022 | $11,068,000 | +99.1% | 237,863 | +144.2% | 0.21% | +38.6% |
Q2 2022 | $5,560,000 | +30.3% | 97,410 | +39.7% | 0.15% | +34.2% |
Q1 2022 | $4,266,000 | +355.8% | 69,719 | +290.0% | 0.11% | +293.1% |
Q4 2021 | $936,000 | -76.0% | 17,878 | -82.9% | 0.03% | -73.6% |
Q3 2021 | $3,893,000 | +8.8% | 104,425 | +19.1% | 0.11% | -9.8% |
Q2 2021 | $3,578,000 | +64.7% | 87,653 | +36.8% | 0.12% | -3.2% |
Q1 2021 | $2,173,000 | +4.5% | 64,054 | -2.1% | 0.13% | -9.4% |
Q4 2020 | $2,080,000 | -72.5% | 65,400 | -70.3% | 0.14% | -71.6% |
Q4 2019 | $7,561,000 | +742.0% | 220,368 | +83.3% | 0.49% | +824.5% |
Q3 2019 | $898,000 | +519.3% | 120,200 | +901.2% | 0.05% | +120.8% |
Q1 2019 | $145,000 | – | 12,005 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |